Alluvi, known as BI 4744, presents a significant advance in obesity care. This dual activator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide targets demonstrates remarkable effectiveness in https://mediajx.com/story865526/alluvi-a-detailed-investigation-into-retatrutide-s-possibilities